The global Thyroid Cancer Drug market is anticipated to reach USD 3.54 billion in 2021 growing at a CAGR of 21.48% during the forecasting period, 2021-2028.
Thyroid cancer is the cancer of the thyroid gland which is located in the neck region of the human body. It is a butterfly-shaped gland that releases 3 hormones 1.triidothyronine (T3) 2.thyroxin (T4) 3.Calcitonin. The thyroid gland uses iodine from the blood to make these hormones and stores and releases the hormones when required. Proper functioning of the thyroid gland is essential for the normal metabolism of the body.
A recent increase in the cases of thyroid cancer and unhealthy lifestyle contributing to the disease prevalence along with the RD in the sector are some of the factors that have supported long-term expansion for the Thyroid Cancer Drug industry.
The global Thyroid Cancer Drug market is segmented into Type, Treatment, Drug Type, Route of Administration, End-Users, and geography.
The type segment is segmented into Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), and Anaplastic Thyroid Cancernal Fixators, Braces, and Prosthesis
Treatment segment is segmented into Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy, and Surgery
The end-User segment is segmented into Hospitals, Homecare, Specialty Clinics, Others
The drug type segment is segmented into Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, and Others
Route of administration segment is segmented into Oral, Injectable, and Others
Geographically, the global Thyroid Cancer Drug market is sub-segmented into North America, Europe, Asia-Pacific, Middle East, and Africa and South America, and insights are provided for each region and major countries within the regions
Key players in the global Thyroid Cancer Drug market are Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc., and Vascular Biogenics among others.
|
Report Feature |
Descriptions |
|---|---|
|
Market Revenue In 2021 |
USD 3.54 billion |
|
Growth Rate |
CAGR of 21.48% during the forecasting period, 2021-2028 |
|
Historical Data |
2018-2019 |
|
Forecast Years |
2021-2028 |
|
Base Year |
2020 |
|
Units Considered |
Revenue in USD billion and CAGR from 2021 to 2028 |
|
Report Segmentation |
Type, Treatment, Drug Type, Route of Administration, End-Users, and Geography |
|
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
|
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and the Middle East and Africa |
|
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe) |
|
Companies Profiled |
Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc., And Vascular Biogenics |
|
Available Customization |
In addition to the market data for the Thyroid Cancer Drug market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirement. |
.png)
.png)
.png)
.png)
.png)
.png)